title: Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
authors.affiliation: Chest Departement, APHP Hôpital Tenon and Pierre et Marie Curie Université Paris 6, Paris, France Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France jacques.cadranel@tnn.aphp.fr.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.affiliation: Chest Departement, APHP Hôpital Tenon and Pierre et Marie Curie Université Paris 6, Paris, France Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.affiliation: Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Langlais
authors.affiliation: Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Morin
authors.affiliation: Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France Thoracic Oncology Dept, APHP Hôpital Bichat and Université Paris 7, Paris, France.
authors.forename: Gérard
authors.initials: G
authors.lastname: Zalcman
mesh_terms: D000230:Adenocarcinoma; D002288:Adenocarcinoma, Mucinous; D006801:Humans; D008175:Lung Neoplasms; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases
chemical_list: D011505:Protein-Tyrosine Kinases